Evidence map›Paper›PMID 34188432›Full record

ArticleCommunications in nonlinear science & numerical simulation2021

Modeling the impact of SARS-CoV-2 variants and vaccines on the spread of COVID-19.

A M Ramos, M Vela-Pérez, M R Ferrández, A B Kubik, B Ivorra

Abstract read
In one paragraph

Article in Communications in nonlinear science & numerical simulation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Modelling herd immunity requirements in Queensland: impact of vaccination effectiveness, hesitancy and variants of SARS-CoV-2.Philosophical transactions. Series A, Mathematical, physical, and engineering sciences · 2022
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

A M RamosMOMAT Research Group, Interdisciplinary Mathematics Institute, Complutense University of Madrid, Spain.
M Vela-PérezMOMAT Research Group, Interdisciplinary Mathematics Institute, Complutense University of Madrid, Spain.
M R FerrándezMOMAT Research Group, Interdisciplinary Mathematics Institute, Complutense University of Madrid, Spain.
A B KubikMOMAT Research Group, Interdisciplinary Mathematics Institute, Complutense University of Madrid, Spain.
B IvorraMOMAT Research Group, Interdisciplinary Mathematics Institute, Complutense University of Madrid, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The continuous mutation of SARS-CoV-2 opens the possibility of the appearance of new variants of the virus with important differences in its spreading characteristics, mortality rates, etc. On 14 December 2020, the United Kingdom reported a potentially more contagious coronavirus variant, present in that country, which is referred to as VOC 202012/01. On 18 December 2020, the South African government also announced the emergence of a new variant in a scenario similar to that of the UK, which is referred to as variant 501.V2. Another important milestone regarding this pandemic was the beginning, in December 2020, of vaccination campaigns in several countries. There are several vaccines, with different characteristics, developed by various laboratories and research centers. A natural question arises: what could be the impact of these variants and vaccines on the spread of COVID-19? Many models have been proposed to simulate the spread of COVID-19 but, to the best of our knowledge, none of them incorporates the effects of potential SARS-CoV-2 variants together with the vaccines in the spread of COVID-19. We develop here a

Indexed as

501.V2COVID-19 vaccineseffective reproduction numberSARS-CoV-2 variantsVOC 202012/01

Identifiers

PMID34188432
PMCPMC8223013

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.